ESA Biosciences to Demonstrate Novel Clinical-Diagnostic Systems at Clinical Lab Expo 2006, Booth #548

ESA Biosciences, Inc., a subsidiary of Magellan Biosciences, Inc., announced that it will feature novel clinical-diagnostic systems at the 2006 Clinical Lab Expo to be held July 25-27 in Chicago.

Contingent upon receipt of CLIA-waiver status, ESA will launch LeadCare II at the show. LeadCare II is an improved version of ESA’s original LeadCare system, the most-widely used blood-lead-testing system by pediatricians, family practitioners, public health, and military clinics worldwide. Waived status will greatly expand the potential sites where lead testing can be performed – for example, in all physician’s offices, as well as community health centers, WIC centers (Women, Infant, and Children program) and mobile clinics, health fairs, or home visits – giving healthcare providers a valuable new tool to better reach those children and adults most at risk for lead poisoning.

LeadCare II removes all the complications formerly associated with blood-lead testing – waiting days for expensive lab results, or spending precious time trying to contact patients for critical follow-up care. The system delivers quantitative blood-lead results, equivalent to those reported by reference laboratories, with only two drops of blood in just three minutes. It is far-simpler to administer than traditional blood-lead tests. It requires only a finger-stick sample, can be combined with other routine waived blood tests, and saves administrative time spent on paper work, tracking, and follow up. Further, since LeadCare II qualifies for reimbursement as a quantitative blood-lead test and the cost per test is actually less than one would pay an outside laboratory, it frees valuable resources to enable individual physicians and lead-poisoning-prevention programs to screen more at-risk children.

ESA will also feature HPLC systems for clinical diagnostics (Plasma Metanephrines, Urine Metanephrines, Urine VMA, 5HIAA and HVA). Its HPLC oncology systems, including the only FDA-cleared system for plasma metanephrine, have been adopted by major clinical laboratories throughout the world to rule out potentially fatal chromaffin cell tumors – usually found in the adrenal glands – with far more sensitivity than traditional assays.

ESA’s HPLC systems for esoteric clinical applications are optimized for cutting-edge research on a wide variety of subjects critical to health and well-being – from Co enzyme Q 10 and the study of fat-soluble vitamins, to the study of xenoestrogens (compounds found in everyday items, such as food and drink packages that mimic the effects of endogenous estrogens).

Visitors can stop by the booth to enter to win a free LeadCare® point-of-care blood-lead analyzer.